NF-κB inhibitors that prevent foam cell formation and atherosclerotic plaque accumulation

Nanomedicine. 2017 Aug;13(6):2037-2048. doi: 10.1016/j.nano.2017.04.013. Epub 2017 Apr 27.

Abstract

The transformation of monocyte-derived macrophages into lipid-laden foam cells is one inflammatory process underlying atherosclerotic disease. Previous studies have demonstrated that fullerene derivatives (FDs) have inflammation-blunting properties. Thus, it was hypothesized that FD could inhibit the transformation process underlying foam cell formation. Fullerene derivatives inhibited the phorbol myristic acid/oxidized low-density lipoprotein-induced differentiation of macrophages into foam cells as determined by lipid staining and morphology.Lipoprotein-induced generation of TNF-α, C5a-induced MC activation, ICAM-1 driven adhesion, and CD36 expression were significantly inhibited in FD treated cells compared to non-treated cells. Inhibition appeared to be mediated through the NF-κB pathway as FD reduced expression of NF-κB and atherosclerosis-associated genes. Compared to controls, FD dramatically inhibited plaque formation in arteries of apolipoprotein E null mice. Thus, FD may be an unrecognized therapy to prevent atherosclerotic lesions via inhibition of foam cell formation and MC stabilization.

Keywords: Atherosclerosis; Foam cells; Fullerenes; Low-density lipoprotein; NF-κB.

MeSH terms

  • Animals
  • Cells, Cultured
  • Foam Cells / drug effects*
  • Foam Cells / metabolism
  • Foam Cells / pathology
  • Fullerenes / pharmacology*
  • Humans
  • Male
  • Mast Cells / drug effects*
  • Mast Cells / metabolism
  • Mast Cells / pathology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout, ApoE
  • NF-kappa B / antagonists & inhibitors*
  • Plaque, Atherosclerotic / metabolism
  • Plaque, Atherosclerotic / pathology
  • Plaque, Atherosclerotic / prevention & control*
  • U937 Cells

Substances

  • Fullerenes
  • NF-kappa B